Loading data for XLO — first visit, this takes a few seconds.
Xilio Therapeutics Inc. (XLO)
NasdaqCM: XLO
· Real-Time Price · USD
9.19
-0.04 (-0.43%)
At close: Aug 25, 2026, 1:46 PM
The price, the headline numbers and the latest news, in one place.
Xilio Therapeutics Inc. (XLO) Stock Price, Analysis & Data
-0.43% (1D)
No data available
| Bid | 9.18 |
| Market Cap | 59.88M |
| Revenue (ttm) | 64.09M |
| Net Income (ttm) | -21.83M |
| -0.12 | |
| -0.32 | |
| n/a | |
| -15.69 | |
| P/B (ttm) | 1.17 |
| P/S (ttm) | 0.93 |
| Earnings Date | n/a |
| Ask | 11.62 |
| Volume | 1,926 |
| Avg. Volume (20D) | 33,716 |
| Open | 9.32 |
| Previous Close | 9.23 |
| Day's Range | 9.17 - 9.32 |
| 52-Week Range | 6.47 - 12.74 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About XLO
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 22, 2021
Employees 76
Stock Exchange NasdaqCM
Ticker Symbol XLO
Website https://xiliotx.com
Financial Performance
In 2025, Xilio Therapeutics's revenue was 43.77M, an increase of 589.88% compared to the previous year's 6.34M. Earnings were -35.04M, a decrease of -39.84%.
Financial StatementsEarnings Surprise
Xilio Therapeutics has released their quarterly earnings on Aug 12, 2026:
- Revenue of $12.65M misses estimates by $0, with 331.67% YoY growth.
- EPS of -0.33 exceeds estimates by 0.26, with 88.21% YoY growth.
Page 1 of 2